Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes

M. Pfeifer, B. Zheng, T. Erdmann, H. Koeppen, R. Mccord, M. Grau, A. Staiger, A. Chai, T. Sandmann, H. Madle, B. Dörken, Y. W. Chu, A. I. Chen, D. Lebovic, G. A. Salles, M. S. Czuczman, M. C. Palanca-Wessels, O. W. Press, R. Advani, F. MorschhauserB. D. Cheson, P. Lenz, G. Ott, A. G. Polson, K. E. Mundt, G. Lenz

Research output: Contribution to journalArticlepeer-review

61 Scopus citations

Fingerprint Dive into the research topics of 'Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes'. Together they form a unique fingerprint.

Medicine & Life Sciences